期刊
LEUKEMIA & LYMPHOMA
卷 51, 期 1, 页码 95-106出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428190903350421
关键词
Bcl-2; CD71; ZAP-70; flow cytometry; CLL; prognostic factors
资金
- Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MURST)
- Programmi di Ricerca di Interesse Nazionale
- Ministero della Salute (Ricerca Finalizzata Istituto di Ricovero e Cura a Carattere Scientifico [IRCCS], Rome, Italy
In chronic lymphocytic leukemia (CLL), inhibition of spontaneous apoptosis determines a worse prognosis and increasing evidences show that disease progression relies also upon cycling CLL cells. We investigated bcl-2, as measure of apoptosis, and CD71, as measure of proliferation, by flow cytometry in 265 patients with CLL. Combining bcl-2 with CD71 values, we defined three subgroups: (1) bcl2 - CD71 -; (2) bcl2 + CD71 +; and (3) bcl2 + CD71 - or bcl2- CD71 +. Both a shorter progression-free survival (PFS) and overall survival (OS) were observed in ZAP-70+ (p < 0.00001) and in patients with bcl2 + CD71+ (p < 0.00001 and p = 0.02). The patients with discordant in bcl2 + CD71 - and bcl2- CD71 + showed an intermediate outcome. Noteworthy, patients with bcl2 + CD71 + showed a shorter PFS within ZAP-70 negative subgroup (p = 0.00009). In multivariate analysis of PFS, age (p = 0.005), beta-(2) microglobulin (B(2)-M) (p = 0.003), bcl-2 (p = 0.004), CD49d (p = 0.001), and ZAP-70 (p < 0.001) resulted to be significant prognostic factors. The independent prognostic significance of B2-M (p = 0.009) and bcl-2 (p = 0.03) was confirmed within ZAP-70 negative patients. Bcl-2 and CD71 can be considered as interesting progression indicators, which should be validated in an independent cohort of patients, to take timely therapeutic decisions in CLL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据